Furthermore, investigations of the pathway showed that HTMCs pretreated with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), downregulated the expression of phase II antioxidative enzymes, partly. 
THERM
Furthermore, investigations of the pathway showed that HTMCs pretreated with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), downregulated the expression of phase II antioxidative enzymes, partly. 
THERM
Furthermore, investigations of the pathway showed that HTMCs pretreated with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), downregulated the expression of phase II antioxidative enzymes, partly. 
THERM
Furthermore, investigations of the pathway showed that HTMCs pretreated with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), downregulated the expression of phase II antioxidative enzymes, partly. 
THERM